Stock Events

Stock Events

Prothena 

$9.39
55
+$0+0% Monday 07:28

Statistics

Day High
9.4
Day Low
9.32
52W High
-
52W Low
-
Volume
314
Avg. Volume
-
Mkt Cap
505.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.69
-0.57
-0.46
-0.35
Expected EPS
-0.348333
Actual EPS
N/A

Financials

-2,520.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
19.37MRevenue
-488.18MNet Income

Analyst Ratings

$24.25Average Price Target
The highest estimate is 36.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRTA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a biotech firm that competes with Prothena in the neurodegenerative diseases space, particularly in developing therapies for Alzheimer's disease.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly is a pharmaceutical company that competes with Prothena in the development of treatments for diseases like Alzheimer's, sharing a focus on neurodegenerative disorders.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG competes in the neurodegenerative disease market, particularly in Alzheimer's and Parkinson's disease treatments, areas of focus for Prothena.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes with Prothena in researching therapies for neurological disorders, including Alzheimer's and Parkinson's diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is involved in developing treatments for serious neurological diseases, competing with Prothena in the neurodegenerative disease research field.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that has initiatives in neurodegenerative diseases, making it a competitor to Prothena in the Alzheimer's and Parkinson's disease areas.
Novartis
NVS
Mkt Cap237.61B
Novartis AG competes with Prothena in the development of novel therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the development of treatments for Alzheimer's disease, directly competing with Prothena's focus on neurodegenerative disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals, Inc. competes with Prothena in developing RNA-targeted therapies for diseases, including neurodegenerative disorders.

About

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Show more...
CEO
ISIN
IE00B91XRN20

Listings

LSE
GB
0Y3M.LSE
BOATS
BOATS
PRTA.BOATS
XNAS
US
PRTA
F
DE
0PT.F

0 Comments

Share your thoughts

FAQ

What is Prothena stock price today?▼
The current price of PRTA.BOATS is $9.39 USD — it has increased by +0% in the past 24 hours. Watch Prothena stock price performance more closely on the chart.
What is Prothena stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Prothena stocks are traded under the ticker PRTA.BOATS.
What is Prothena market cap?▼
Today Prothena has the market capitalization of 505.49M
When is the next Prothena earnings date?▼
Prothena is going to release the next earnings report on May 13, 2026.
What were Prothena earnings last quarter?▼
PRTA.BOATS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.56 USD resulting in a +28.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prothena revenue for the last year?▼
Prothena revenue for the last year amounts to 19.37M USD.
What is Prothena net income for the last year?▼
PRTA.BOATS net income for the last year is -488.18M USD.
When did Prothena complete a stock split?▼
Prothena has not had any recent stock splits.